Pharmacokinetics of indinavir in Koreans and Caucasians

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 4, 2004, Pages 307-309

  Choi, Jun Yong ^a   Chang, Kyung Hee ^a   Park, Yoon Soo ^a   Cho, Cheong Ho ^a   Shin, So Youn ^a   Song, Young Goo ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; INDINAVIR; NIFEDIPINE; PROTEINASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ETHNIC DIFFERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; KOREA; LIPODYSTROPHY; MALE; NORMAL HUMAN; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE;

EID: 2642520388     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410019697     Document Type: Article

References (14)

1. Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 2000; 36: 275-81.
2. Zhou HH, Liu ZQ. Ethnic differences in drug metabolism. Clin Chem Lab Med 2000; 38: 899-903.
3. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350-73.
4. Chang KH, Kim JM, Song YG, Hong SK, Lee HC, Lim SK. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? J Infection 2002; 44: 33-8.
5. Svensson JO, Sönnerborg A, Stable L. Rapid and simple determination of indinavir in serum, urine, and cerebrospinal fluid using high-performance liquid chromatography. Ther Drug Monit 2000; 22: 626-9.
6. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
7. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W, Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999; 25: 383-92.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
9. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycaemia, hyperlipidaemia and lipodystrophy. Arch Intern Med 2000; 160: 2050-6.
10. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-53.
11. Tomori T, Minoru W, Hironori N, Masako A, Hiroaki S, Yoshihiro M, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001; 69: 333-9.
12. Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, et al. Ethnic differences and relationships in the oral pharmacokinetics of nefedipine and erythromycin. Clin Pharmacol Ther 2001; 70: 228-36.
13. Liyue H, Stephen AW, Joseph LW, Kenneth RB, Cosette S, Joseph WP. Induction of P-glycoprotein and cytochrome P450 by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754-60.
14. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-310.